# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global P...
Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateauPotential for best-in-class tolerability with min...
Leerink Partners analyst David Risinger downgrades Metsera (NASDAQ:MTSR) from Outperform to Market Perform and lowers the pr...
Pfizer will buy Metsera for $4.9 billion plus milestone payments, adding incretin, amylin, and oral obesity drug candidates to ...
- Reuters Cites Conf Call